Protagenic Inventory vs Short Term Debt Analysis

PTIXW Stock

USD 0.01 0.00 0.00%

Protagenic Therapeutics financial indicator trend analysis is much more than just breaking down Protagenic Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protagenic Therapeutics is a good investment. Please check the relationship between Protagenic Therapeutics Inventory and its Short Term Debt accounts. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Inventory vs Short Term Debt

Inventory vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protagenic Therapeutics Inventory account and Short Term Debt. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Protagenic Therapeutics' Inventory and Short Term Debt is 0.4. Overlapping area represents the amount of variation of Inventory that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Protagenic Therapeutics, assuming nothing else is changed. The correlation between historical values of Protagenic Therapeutics' Inventory and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory of Protagenic Therapeutics are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Inventory i.e., Protagenic Therapeutics' Inventory and Short Term Debt go up and down completely randomly.

Correlation Coefficient

0.4

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Inventory

Short Term Debt

Most indicators from Protagenic Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protagenic Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Selling General Administrative is likely to drop to about 1.1 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year

	2021	2023	2024 (projected)
Total Operating Expenses	4.1M	4.5M	5.7M
Cost Of Revenue	30.0	28.2K	26.8K

Total Operating Expenses Cost Of Revenue

Protagenic Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Intangible Assets
Total Assets		0.02	0.43	-0.15	0.63	0.58	-0.02	0.19	0.08	0.57	0.57	0.72	-0.48	-0.48	0.71	-0.2	0.57	0.68	-0.12	-0.17	0.88	0.12	-0.24	-0.23	0.81	-0.27
Short Long Term Debt Total	0.02		-0.06	0.88	-0.7	0.36	0.76	-0.8	-0.08	0.37	0.36	-0.31	-0.41	-0.41	-0.26	0.87	0.37	-0.16	0.79	0.89	-0.18	0.94	0.83	0.83	-0.18	-0.35
Other Current Liab	0.43	-0.06		-0.31	0.47	0.64	-0.24	0.39	0.28	0.64	0.63	-0.01	-0.54	-0.53	0.63	-0.38	0.64	0.24	-0.37	-0.32	0.22	-0.02	-0.41	-0.43	-0.06	-0.29
Total Current Liabilities	-0.15	0.88	-0.31		-0.86	0.01	0.64	-0.98	-0.03	0.01	0.0	-0.21	-0.07	-0.07	-0.42	1.0	0.01	-0.33	0.97	1.0	-0.21	0.92	0.99	0.99	-0.14	-0.11
Total Stockholder Equity	0.63	-0.7	0.47	-0.86		0.28	-0.54	0.85	0.1	0.27	0.27	0.54	-0.16	-0.16	0.71	-0.88	0.27	0.58	-0.81	-0.87	0.64	-0.66	-0.9	-0.89	0.53	0.03
Property Plant And Equipment Net	0.58	0.36	0.64	0.01	0.28		0.29	0.16	-0.05	1.0	1.0	-0.15	-0.92	-0.92	0.35	-0.05	1.0	0.27	-0.14	0.0	0.2	0.4	-0.11	-0.12	0.05	-0.59
Net Debt	-0.02	0.76	-0.24	0.64	-0.54	0.29		-0.55	-0.69	0.31	0.31	-0.31	-0.42	-0.42	-0.31	0.65	0.31	0.0	0.54	0.66	-0.23	0.68	0.61	0.61	-0.06	-0.43
Retained Earnings	0.19	-0.8	0.39	-0.98	0.85	0.16	-0.55		-0.03	0.16	0.17	0.11	-0.13	-0.13	0.37	-0.98	0.16	0.34	-1.0	-0.98	0.15	-0.84	-0.99	-0.99	0.09	-0.07
Cash	0.08	-0.08	0.28	-0.03	0.1	-0.05	-0.69	-0.03		-0.07	-0.09	0.17	0.22	0.22	0.21	-0.06	-0.07	-0.14	0.05	-0.04	0.23	-0.02	-0.03	-0.04	-0.06	0.39
Non Current Assets Total	0.57	0.37	0.64	0.01	0.27	1.0	0.31	0.16	-0.07		1.0	-0.16	-0.94	-0.94	0.33	-0.04	1.0	0.27	-0.14	0.0	0.18	0.4	-0.1	-0.11	0.05	-0.62
Non Currrent Assets Other	0.57	0.36	0.63	0.0	0.27	1.0	0.31	0.17	-0.09	1.0		-0.16	-0.95	-0.95	0.31	-0.05	1.0	0.28	-0.15	0.0	0.17	0.39	-0.11	-0.12	0.04	-0.64
Cash And Short Term Investments	0.72	-0.31	-0.01	-0.21	0.54	-0.15	-0.31	0.11	0.17	-0.16	-0.16		0.21	0.22	0.59	-0.22	-0.16	0.56	-0.05	-0.22	0.91	-0.21	-0.22	-0.2	0.94	0.21
Net Receivables	-0.48	-0.41	-0.54	-0.07	-0.16	-0.92	-0.42	-0.13	0.22	-0.94	-0.95	0.21		1.0	-0.12	-0.03	-0.94	-0.26	0.13	-0.07	-0.04	-0.41	0.04	0.05	0.0	0.82
Good Will	-0.48	-0.41	-0.53	-0.07	-0.16	-0.92	-0.42	-0.13	0.22	-0.94	-0.95	0.22	1.0		-0.12	-0.03	-0.94	-0.26	0.13	-0.07	-0.04	-0.41	0.04	0.05	0.0	0.82
Common Stock Shares Outstanding	0.71	-0.26	0.63	-0.42	0.71	0.35	-0.31	0.37	0.21	0.33	0.31	0.59	-0.12	-0.12		-0.46	0.32	0.37	-0.31	-0.43	0.74	-0.2	-0.48	-0.48	0.52	0.14
Non Current Liabilities Total	-0.2	0.87	-0.38	1.0	-0.88	-0.05	0.65	-0.98	-0.06	-0.04	-0.05	-0.22	-0.03	-0.03	-0.46		-0.04	-0.34	0.97	1.0	-0.24	0.89	1.0	1.0	-0.15	-0.09
Inventory	0.57	0.37	0.64	0.01	0.27	1.0	0.31	0.16	-0.07	1.0	1.0	-0.16	-0.94	-0.94	0.32	-0.04		0.28	-0.14	0.01	0.18	0.4	-0.1	-0.11	0.04	-0.63
Other Current Assets	0.68	-0.16	0.24	-0.33	0.58	0.27	0.0	0.34	-0.14	0.27	0.28	0.56	-0.26	-0.26	0.37	-0.34	0.28		-0.3	-0.32	0.63	-0.2	-0.36	-0.36	0.65	-0.18
Other Stockholder Equity	-0.12	0.79	-0.37	0.97	-0.81	-0.14	0.54	-1.0	0.05	-0.14	-0.15	-0.05	0.13	0.13	-0.31	0.97	-0.14	-0.3		0.97	-0.07	0.84	0.98	0.98	-0.02	0.09
Total Liab	-0.17	0.89	-0.32	1.0	-0.87	0.0	0.66	-0.98	-0.04	0.0	0.0	-0.22	-0.07	-0.07	-0.43	1.0	0.01	-0.32	0.97		-0.22	0.91	0.99	0.99	-0.15	-0.12
Total Current Assets	0.88	-0.18	0.22	-0.21	0.64	0.2	-0.23	0.15	0.23	0.18	0.17	0.91	-0.04	-0.04	0.74	-0.24	0.18	0.63	-0.07	-0.22		-0.07	-0.25	-0.24	0.92	0.19
Short Term Debt	0.12	0.94	-0.02	0.92	-0.66	0.4	0.68	-0.84	-0.02	0.4	0.39	-0.21	-0.41	-0.41	-0.2	0.89	0.4	-0.2	0.84	0.91	-0.07		0.86	0.86	-0.08	-0.32
Common Stock	-0.24	0.83	-0.41	0.99	-0.9	-0.11	0.61	-0.99	-0.03	-0.1	-0.11	-0.22	0.04	0.04	-0.48	1.0	-0.1	-0.36	0.98	0.99	-0.25	0.86		1.0	-0.16	-0.04
Accounts Payable	-0.23	0.83	-0.43	0.99	-0.89	-0.12	0.61	-0.99	-0.04	-0.11	-0.12	-0.2	0.05	0.05	-0.48	1.0	-0.11	-0.36	0.98	0.99	-0.24	0.86	1.0		-0.14	-0.04
Short Term Investments	0.81	-0.18	-0.06	-0.14	0.53	0.05	-0.06	0.09	-0.06	0.05	0.04	0.94	0.0	0.0	0.52	-0.15	0.04	0.65	-0.02	-0.15	0.92	-0.08	-0.16	-0.14		0.07
Intangible Assets	-0.27	-0.35	-0.29	-0.11	0.03	-0.59	-0.43	-0.07	0.39	-0.62	-0.64	0.21	0.82	0.82	0.14	-0.09	-0.63	-0.18	0.09	-0.12	0.19	-0.32	-0.04	-0.04	0.07

Click cells to compare fundamentals

Protagenic Therapeutics Account Relationship Matchups

Protagenic Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	842.3K	879.2K	11.1M	8.0M	4.3M	4.1M
Other Current Liab	1.2M	513.3K	520.6K	105.9K	655.1K	622.4K
Total Current Liabilities	1.2M	655.2K	799.5K	1.1M	655.3K	622.5K
Total Stockholder Equity	(634.4K)	(1.1M)	9.9M	6.9M	3.7M	6.1M
Property Plant And Equipment Net	611.0	296.0	0.0	1.8K	123.3K	117.2K
Net Debt	(519.3K)	702.7K	(222.7K)	129.0K	(1.3M)	(1.4M)
Retained Earnings	(15.2M)	(17.7M)	(22.2M)	(25.8M)	(30.8M)	(32.3M)
Cash	798.6K	671.1K	541.2K	215.2K	1.3M	2.0M
Non Current Assets Total	611.0	296.0	0.0	1.8K	123.3K	117.2K
Cash And Short Term Investments	798.6K	671.1K	10.4M	8.0M	4.1M	3.9M
Liabilities And Stockholders Equity	842.3K	879.2K	11.1M	8.0M	4.3M	4.1M
Non Current Liabilities Total	52.4K	279.4K	1.4M	318.4K	1.0M	0.0
Other Current Assets	43.4K	208.2K	688.7K	56.9K	144.0K	136.8K
Other Stockholder Equity	14.7M	16.7M	32.4M	33.4M	34.6M	41.2M
Total Liab	1.5M	2.0M	1.1M	1.1M	655.3K	622.5K
Total Current Assets	842.0K	879.2K	11.1M	8.0M	4.2M	7.5M
Accumulated Other Comprehensive Income	(172.4K)	(171.6K)	(248.3K)	(676.9K)	(113.5K)	(119.2K)
Accounts Payable	36.2K	141.9K	278.9K	669.7K	113.8	108.11
Net Invested Capital	(355.0K)	224.1K	10.3M	7.3M	3.7M	3.5M
Net Working Capital	(355.3K)	224.1K	10.3M	6.9M	3.5M	3.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
CRM	Salesforce
S	SentinelOne

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protagenic Inventory vs Short Term Debt Analysis

Inventory vs Short Term Debt

Inventory vs Short Term Debt Correlation Analysis

Correlation Coefficient

Inventory

Short Term Debt

Protagenic Therapeutics fundamental ratios Correlations

Protagenic Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protagenic Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Protagenic Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Non Currrent Assets Other	+ 1.0	Property Plant And Equipment Net
Inventory	+ 1.0	Property Plant And Equipment Net
Non Currrent Assets Other	+ 1.0	Non Current Assets Total

Other Stockholder Equity	- 1.0	Retained Earnings
Accounts Payable	- 0.99	Retained Earnings
Common Stock	- 0.99	Retained Earnings
Total Liab	- 0.98	Retained Earnings
Non Current Liabilities Total	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities